IL319478A - Anti-ccr8 antibodies - Google Patents
Anti-ccr8 antibodiesInfo
- Publication number
- IL319478A IL319478A IL319478A IL31947825A IL319478A IL 319478 A IL319478 A IL 319478A IL 319478 A IL319478 A IL 319478A IL 31947825 A IL31947825 A IL 31947825A IL 319478 A IL319478 A IL 319478A
- Authority
- IL
- Israel
- Prior art keywords
- ccr8
- antibody
- antibodies
- seq
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163226118P | 2021-07-27 | 2021-07-27 | |
| PCT/US2022/074214 WO2023010054A1 (en) | 2021-07-27 | 2022-07-27 | Anti-ccr8 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL319478A true IL319478A (en) | 2025-05-01 |
Family
ID=82898810
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL319478A IL319478A (en) | 2021-07-27 | 2022-07-27 | Anti-ccr8 antibodies |
| IL307533A IL307533B2 (en) | 2021-07-27 | 2022-07-27 | Anti-ccr8 antibodies |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL307533A IL307533B2 (en) | 2021-07-27 | 2022-07-27 | Anti-ccr8 antibodies |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US11639393B2 (https=) |
| EP (2) | EP4491635A3 (https=) |
| JP (2) | JP7638935B2 (https=) |
| KR (2) | KR20250135339A (https=) |
| CN (1) | CN117425677A (https=) |
| AR (1) | AR126578A1 (https=) |
| AU (1) | AU2022317803A1 (https=) |
| BR (1) | BR112023024837A2 (https=) |
| CA (1) | CA3220121A1 (https=) |
| CO (1) | CO2023015915A2 (https=) |
| DK (1) | DK4214240T3 (https=) |
| ES (1) | ES2995868T3 (https=) |
| FI (1) | FI4214240T3 (https=) |
| HR (1) | HRP20241561T1 (https=) |
| HU (1) | HUE069018T2 (https=) |
| IL (2) | IL319478A (https=) |
| LT (1) | LT4214240T (https=) |
| MX (1) | MX2023014154A (https=) |
| PL (1) | PL4214240T3 (https=) |
| PT (1) | PT4214240T (https=) |
| RS (1) | RS66234B1 (https=) |
| SA (1) | SA523451582B1 (https=) |
| SI (1) | SI4214240T1 (https=) |
| SM (1) | SMT202400483T1 (https=) |
| WO (1) | WO2023010054A1 (https=) |
| ZA (1) | ZA202309516B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| CN120076829A (zh) | 2022-10-18 | 2025-05-30 | 明治制果药业株式会社 | T细胞肿瘤的治疗剂 |
| EP4661869A1 (en) | 2023-02-06 | 2025-12-17 | Bayer Aktiengesellschaft | Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators |
| JPWO2024248037A1 (https=) | 2023-05-30 | 2024-12-05 | ||
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025186043A1 (en) | 2024-03-06 | 2025-09-12 | Bayer Aktiengesellschaft | Pharmaceutical formulation for anti-ccr8 antibodies |
| WO2025259871A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| US10087259B1 (en) | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
| EP4092045A1 (en) | 2016-05-16 | 2022-11-23 | Checkmab S.R.L. | Markers selectively deregulated in tumor-infiltrating regulatory t cells |
| WO2018112032A1 (en) | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8 |
| ES2863412T3 (es) | 2017-03-29 | 2021-10-11 | Shionogi & Co | Composición farmacéutica para el tratamiento del cáncer |
| WO2020138489A1 (ja) * | 2018-12-27 | 2020-07-02 | 塩野義製薬株式会社 | 新規抗ｃｃｒ８抗体 |
| CA3160204A1 (en) | 2020-01-06 | 2021-07-15 | Vaccinex, Inc. | Anti-ccr8 antibodies and uses thereof |
| TWI890283B (zh) * | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| US20250019449A1 (en) | 2020-03-05 | 2025-01-16 | Memorial Sloan Kettering Cancer Center | Anti-ccr8 agents |
| AU2021244200A1 (en) | 2020-03-23 | 2022-11-24 | Bristol-Myers Squibb Company | Anti-CCR8 antibodies for treating cancer |
| TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
| WO2022003156A1 (en) | 2020-07-02 | 2022-01-06 | Oncurious Nv | Ccr8 non-blocking binders |
| EP4186926A4 (en) | 2020-08-28 | 2024-06-05 | Harbour Biomed US, Inc. | ANTI-CCR8 ANTIBODIES AND CORRESPONDING APPLICATION |
| CA3198456A1 (en) | 2020-10-14 | 2022-04-21 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
| EP4010378B1 (en) | 2020-10-16 | 2026-05-06 | LaNova Medicines Limited | Anti-ccr8 monoclonal antibodies and uses thereof |
| CA3206124A1 (en) | 2020-12-24 | 2022-06-30 | Vib Vzw | Non-blocking human ccr8 binders |
| WO2022136647A1 (en) | 2020-12-24 | 2022-06-30 | Oncurious Nv | Human ccr8 binders |
-
2022
- 2022-07-27 FI FIEP22754752.8T patent/FI4214240T3/fi active
- 2022-07-27 US US17/815,505 patent/US11639393B2/en active Active
- 2022-07-27 HU HUE22754752A patent/HUE069018T2/hu unknown
- 2022-07-27 LT LTEPPCT/US2022/074214T patent/LT4214240T/lt unknown
- 2022-07-27 DK DK22754752.8T patent/DK4214240T3/da active
- 2022-07-27 EP EP24198142.2A patent/EP4491635A3/en active Pending
- 2022-07-27 PT PT227547528T patent/PT4214240T/pt unknown
- 2022-07-27 SM SM20240483T patent/SMT202400483T1/it unknown
- 2022-07-27 JP JP2022119632A patent/JP7638935B2/ja active Active
- 2022-07-27 RS RS20241306A patent/RS66234B1/sr unknown
- 2022-07-27 BR BR112023024837A patent/BR112023024837A2/pt active Search and Examination
- 2022-07-27 CN CN202280040102.9A patent/CN117425677A/zh active Pending
- 2022-07-27 MX MX2023014154A patent/MX2023014154A/es unknown
- 2022-07-27 PL PL22754752.8T patent/PL4214240T3/pl unknown
- 2022-07-27 KR KR1020257028953A patent/KR20250135339A/ko active Pending
- 2022-07-27 WO PCT/US2022/074214 patent/WO2023010054A1/en not_active Ceased
- 2022-07-27 AU AU2022317803A patent/AU2022317803A1/en active Pending
- 2022-07-27 IL IL319478A patent/IL319478A/en unknown
- 2022-07-27 EP EP22754752.8A patent/EP4214240B1/en active Active
- 2022-07-27 CA CA3220121A patent/CA3220121A1/en active Pending
- 2022-07-27 IL IL307533A patent/IL307533B2/en unknown
- 2022-07-27 AR ARP220101985A patent/AR126578A1/es unknown
- 2022-07-27 HR HRP20241561TT patent/HRP20241561T1/hr unknown
- 2022-07-27 SI SI202230078T patent/SI4214240T1/sl unknown
- 2022-07-27 ES ES22754752T patent/ES2995868T3/es active Active
- 2022-07-27 KR KR1020237041895A patent/KR102860769B1/ko active Active
-
2023
- 2023-10-11 ZA ZA2023/09516A patent/ZA202309516B/en unknown
- 2023-11-19 SA SA523451582A patent/SA523451582B1/ar unknown
- 2023-11-22 CO CONC2023/0015915A patent/CO2023015915A2/es unknown
-
2025
- 2025-02-18 JP JP2025023976A patent/JP2025081477A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL307533B2 (en) | Anti-ccr8 antibodies | |
| US11660340B2 (en) | Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function | |
| US11505605B2 (en) | T cell-redirected antigen-binding molecule for cells having immunosuppression function | |
| US11649293B2 (en) | Method for enhancing humoral immune response | |
| KR20210143192A (ko) | 변형된 Fc 단편, 이를 포함하는 항체 및 이의 응용 | |
| CN106459206A (zh) | 免疫活化抗原结合分子 | |
| IL293385A (en) | New anti–pd–1 antibodies | |
| EP4493592A1 (en) | Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells | |
| US12435159B2 (en) | Anti-human GRP94 antibodies and uses | |
| TWI920354B (zh) | 抗ｃｃｒ８抗體 | |
| CN117203341A (zh) | 用于治疗或预防炎症性疾病的抗人pd-1激动剂抗体和含有其的药物组合物 | |
| TW202611084A (zh) | 抗ccr8抗體 | |
| HK40100657B (en) | Anti-ccr8 antibodies | |
| HK40100657A (en) | Anti-ccr8 antibodies | |
| BR122025022218A2 (pt) | Anticorpo anti-ccr8 e composição farmacêutica | |
| BR122024013309B1 (pt) | Anticorpos anti-ccr8 e composição compreendendo os mesmos | |
| BR122024013309A2 (pt) | Anticorpos anti-ccr8 e composição compreendendo os mesmos | |
| KR20260047587A (ko) | 항-ox40l 항체 및 이의 용도 |